John Evans
AstraZeneca
5 Papers
45 Citations
John Evans is an academic researcher from AstraZeneca. The author has contributed to research in topics: Tesaglitazar & Hamster. The author has an hindex of 5, co-authored 5 publications.
Chat about Author
Papers
An Analysis of Pharmaceutical Experience with Decades of Rat Carcinogenicity Testing: Support for a Proposal to Modify Current Regulatory Guidelines
Frank D. Sistare,Daniel Morton,Carl L. Alden,Joel Christensen,Douglas A. Keller,Sandra De Jonghe,Richard D. Storer,M. Vijayaraj Reddy,Andrew R. Kraynak,Bruce A. Trela,Jean-Guy Bienvenu,Sivert Bjurström,Vanessa Bosmans,David Brewster,Karyn Colman,Mark A. Dominick,John Evans,James R. Hailey,Lewis B. Kinter,Matt Liu,Charles R. Mahrt,Dirk Mariën,James R. Myer,Richard Perry,Daniel Potenta,Arthur Roth,Philip Sherratt,Thomas Singer,Rabih Slim,Keith A. Soper,Ronny Fransson-Steen,James H. Stoltz,Oliver C. Turner,Susan E. Turnquist,Marjolein van Heerden,Jochen Woicke,Joseph J. DeGeorge +36 more
TL;DR: A proposal to refine regulatory criteria for conducting a two-year rat study to be based on assessment of histopathologic findings from a rat six- month study, evidence of hormonal perturbation, genetic toxicology results, and the findings of a six-month transgenic mouse carcinogenicity study has the potential to eliminate over 40% of rat two- year testing on new pharmaceuticals without compromise to patient safety.
155
The histology and development of hepatic nodules and carcinoma in C3H/He and C57BL/6 mice following chronic phenobarbitone administration.
TL;DR: It is concluded that both strains of mice behave in a qualitively similar way to PB administration, although they show considerable quantitative differences in terms of the time and number of nodules that develop.
32
Tesaglitazar, a Dual PPAR-α/γ Agonist, Hamster Carcinogenicity, Investigative Animal and Clinical Studies:
Per Lindblom,Anna-Lena Berg,Hui Zhang,Rolf Westerberg,Jonathan Tugwood,Hanna Lundgren,Maritha Marcusson-Ståhl,Niclas Sjögren,Bo Blomgren,Peter Öhman,Inger Skånberg,John Evans,Heike Hellmold +12 more
TL;DR: Investigations have demonstrated that tesaglitazar does not produce hemangiosarcomas in hamster despite a slight effect on vascular morphology in the liver, as well as in vitro administration to ECs.
14
Tesaglitazar, a PPARα/γ Agonist, Induces Interstitial Mesenchymal Cell DNA Synthesis and Fibrosarcomas in Subcutaneous Tissues in Rats
Heike Hellmold,Hui Zhang,Ulf Andersson,Bo Blomgren,Tom Holland,Anna-Lena Berg,Marie Elebring,Niclas Sjögren,Krister Bamberg,Björn Dahl,Rolf Westerberg,Birgitta Dillner,Jonathan Tugwood,Ruth A. Roberts,Erik Lundholm,Germán Camejo,Inger Skånberg,John Evans +17 more
TL;DR: The results suggest that the induction of rat fibrosarcoma by tesaglitazar, at exposures 100-fold above the human therapeutic exposure, may involve proliferation of undifferentiated mesenchymal cells in subcutaneous tissues.
Comparison of the hepatic effects of nafenopin and WY-14,643 on peroxisome proliferation and cell replication in the rat and Syrian hamster.
TL;DR: The rat study demonstrates that liver tumors are produced more rapidly by doses of peroxisome proliferators that produce a sustained stimulation of cell replication, whereas the hamster study suggests that species differences may exist in both peroxISome proliferator-induced cell replication and liver tumor formation.